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I2S2 is a randomised controlled trial of iodine supplemen-
tation in preterm infants examining whether iodine sup-
plementation can improve neurodevelopmental outcome
at two years of age. 20 Neonatal Units in the UK will
recruit around 1400 infants <31 weeks of gestation into
the trial; infants will receive a daily dose of sodium iodide
or sodium chloride placebo until 34 week’s corrected age.
Due to the nature of neonatal care, approximately 50%
of infants participating in I2S2 are likely to be trans-
ferred from the ‘Recruiting Site’ to another hospital for
continuation of their clinical care. Hospitals which are
not the primary research site may receive infants with
little warning and be required to continue treatment
under the trial protocol. Hospitals which are research
active but have a reduced level of involvement have
been defined as ‘Continuing Care Sites’ and ‘Data Col-
lection Sites’; such sites require Research Management
and Governance review proportionate to their level of
involvement in the clinical trial.
This three-tiered approach was negotiated between the
NPEU Clinical Trials Unit, R&D Forum and the
National Institute for Health Research Clinical Research
Network Coordinating Centre (NIHR CRN CC), with
contributions from and supported by the Birmingham
and Black Country Comprehensive Local Research Net-
work (BBC CLRN) and the University of Oxford. It was
approved by the Medicines and Healthcare products
Regulatory Agency and Research Ethics Service as part
of a substantial amendment. The use of a generic Site-
Specific Information (SSI) and supporting document
entitled ‘Statement of Responsibilities’ clearly defines
site involvement, NHS permission and funding; both
documents negate the need for site agreements with the
sponsor. NHS permissions are granted for each Neona-
tal Unit across the UK; those sites without identified
Principal Investigators issue provisional NHS Trust
approval with confirmation of Principal Investigator on
point of transfer. Appropriate trial specific training
materials are provided to all sites including training in
the reporting of SAE’s and SUSAR’s.
This approach allows NHS permissions to be issued in
advance of any transfer and ensures infants recruited to
I2S2 can continue trial procedures at different sites.
Withdrawing an infant from the trial because regulatory
and research governance paperwork is not in place,
seems a wasted effort for all individuals involved, and
more importantly unethical to parents. This streamlined,
pragmatic approach to governance review has proved a
successful strategy from which many can learn.
Trial registry [http://www.clinicaltrials.gov]; Identifier:
NCT00638092. Funded by UK Medical Research Council.
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